Spyre Therapeutics, Inc. (SYRE) Stock
SYRE Key Statistics
About Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor necrosis factor-like ligand 1A (TL1A). A synergistic approach is also being explored with SPY120, a compound that merges the anti-a4ß7 action of SPY001 with the anti-TL1A activity of SPY002. All these programs are currently undergoing preclinical evaluation. Beyond these, the company's early-stage portfolio encompasses several additional promising candidates: SPY003, an anti-IL-23 monoclonal antibody; SPY004, a monoclonal antibody with a novel mechanism of action; SPY130, which combines anti-a4ß7 and anti-IL-23 antibodies; and SPY230, a dual antibody therapy featuring anti-TL1A and anti-IL-23 components. Originally incorporated in 2013, the organization was previously known as Aeglea BioTherapeutics, Inc., before rebranding to Spyre Therapeutics, Inc. in November 2023. Its headquarters are located in Waltham, Massachusetts.
CEO: Cameron Turtle. Company website
SYRE — Frequently Asked Questions
What is the SYRE stock price today?
Spyre Therapeutics, Inc. (SYRE) trades at $90.25, down 2.62% on the day, as of Sep 20, 2026 14:57 UTC.
What is Spyre Therapeutics, Inc.'s market cap?
Spyre Therapeutics, Inc. has a market capitalisation of $7.84B, calculated from the live SYRE share price and shares outstanding.
What is the P/E ratio of SYRE?
SYRE has no meaningful price-to-earnings ratio: Spyre Therapeutics, Inc. lost $1.95 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Spyre Therapeutics, Inc. make?
Spyre Therapeutics, Inc. generated revenue of $90.49M over the trailing twelve months, which puts the stock at 86.61 times sales.
What is the 52-week range for SYRE?
SYRE has traded between $14.51 and $110.18 over the past 52 weeks, and the last price is 18.1% below that high.
Is Spyre Therapeutics, Inc. profitable?
No. Spyre Therapeutics, Inc. is loss-making, with a net margin of -197.71% over the trailing twelve months.
What is the analyst price target for SYRE?
Wall Street analysts rate SYRE Buy, with an average price target of $111.82, 23.9% above the current price.
What sector is Spyre Therapeutics, Inc. in?
Spyre Therapeutics, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Spyre Therapeutics, Inc.?
Cameron Turtle is the chief executive of Spyre Therapeutics, Inc., which employs 125 people.
Where can I track SYRE in real time?
QFI Terminal shows SYRE with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See SYRE live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open SYRE in Terminal See plans